Photocure establishes Named Patient Program to provide access to Hexvix in South Africa
Photocure establishes Named Patient Program to provide access to Hexvix in South Africa |
[27-September-2024] |
OSLO, Norway, Sept. 27, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it entered into an agreement with Equity Pharmaceuticals PTY Limited, part of the Clinigen group, in September, to initiate a Named Patient Program (NPP) enabling bladder cancer patients in South Africa to receive blue light cystoscopy (BLC®) with Hexvix®. Named Patient Programs (NPPs) provide access to medicines in response to requests by physicians on behalf of specific, or 'named,' patients when those medicines are not licensed or available in the patients' home country. Photocure's NPP with Equity Pharmaceuticals is designed to ensure that physicians can request Hexvix on behalf of individual patients residing in South Africa, with suspected or recurring bladder tumors. Hexvix blue light cystoscopy is indicated as adjunct to standard white light cystoscopy to contribute to the diagnosis and management of bladder cancer in patients with known or high suspicion of bladder cancer. "Without this NPP, BLC with Hexvix would not otherwise be available to bladder cancer patients in South Africa. Photocure is committed to ensuring global access to Hexvix as part of its sustainability goals," said Dan Schneider, President and CEO of Photocure. "We see this program as a stepstone to trialing various ways in which Hexvix can be made available to patients and urologists in countries where BLC equipment is already accessible." Note to editors: All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA. About Bladder Cancer Bladder cancer ranks as the 8th most common cancer worldwide – the 5th most common in men – with 1,949,000 prevalent cases (5-year prevalence rate)1a, 6,14,000 new cases and more than 2,20,000 deaths in 2022.1b 1 Globocan. a) 5-year prevalence / b) incidence/mortality by population. Available at: https://gco.iarc.fr/today, accessed [February 2024]. About Hexvix®/Cysview® (hexaminolevulinate HCl) Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the bladder, making them glow bright pink during Blue Light Cystoscopy (BLC®). BLC with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves the detection of tumors and leads to more complete resection, fewer residual tumors, and better management decisions. About Photocure ASA Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com, www.cysview.com. About Clinigen Clinigen is a global, specialist pharmaceutical services company focused on providing ethical access to medicines. Its mission is to accelerate access to medicines for patients in every corner of the globe. The Group supports pharmaceutical and biotech companies across the medical product lifecycle, from clinical through to commercial and operates from sites in North America, Europe, Africa and the Asia Pacific. Clinigen has more than 1,000 employees across five continents in 15 countries and provides access in more than 130 countries every year. For more information on Clinigen, please visit http://www.clinigengroup.com. For further information, please contact: Dan Schneider Erik Dahl David Moskowitz Media and IR enquiries: Geir Bjørlo This information was brought to you by Cision http://news.cision.com The following files are available for download:
View original content:https://www.prnewswire.com/news-releases/photocure-establishes-named-patient-program-to-provide-access-to-hexvix-in-south-africa-302260845.html SOURCE Photocure | ||
Company Codes: Bloomberg:PHO@NO, ISIN:NO0010000045, Oslo:PHO, RICS:PHO.OL |